Drug-coated balloons for restenosis prophylaxis

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Biomaterials Science

Background:

• Drug-coated balloons (DCBs) offer localized drug delivery, minimizing systemic exposure for restenosis prophylaxis.
• Development was influenced by drug-eluting stents, leveraging prior experience in drug selection and testing methodologies.
• Current DCBs primarily utilize paclitaxel (approx. 3 µg/mm²) with various excipients to modulate drug adherence and release.

Purpose of the Study:

• To evaluate the efficacy and safety of drug-coated balloons in preventing restenosis.
• To assess the long-term outcomes of DCB treatment in coronary and peripheral arteries.
• To understand the mechanisms behind the persistent efficacy of paclitaxel-coated balloons.

Main Methods:

• Review of animal studies and randomized clinical trials (RCTs) involving DCBs.
• Analysis of DCB technology, including drug formulation (paclitaxel) and coating additives.
• Assessment of clinical endpoints such as neointimal proliferation, restenosis rates, and revascularization necessity.

Main Results:

• DCBs demonstrated effective reduction in neointimal proliferation and restenosis in both coronary and peripheral arteries.
• Sustained efficacy was observed for up to 2-5 years in clinical studies.
• No coating-related adverse events were reported in clinical trials, indicating a favorable safety profile.

Conclusions:

• Drug-coated balloons are effective and safe for preventing restenosis, particularly in coronary in-stent restenosis and peripheral artery disease.
• The long-term efficacy may be attributed to prolonged paclitaxel residence time or early inhibition of proliferative pathways.
• DCBs represent a valuable therapeutic option in interventional cardiology for managing arterial restenosis.